{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:42:22Z","timestamp":1794624142703,"version":"4.9.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016492","name":"Kiniksa Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.eclinm.2023.101826","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T18:44:58Z","timestamp":1675449898000},"page":"101826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7789-6915","authenticated-orcid":false,"given":"Howard","family":"Sofen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bissonnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Tyring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Jing","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Zook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangxing","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Liang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eclinm.2023.101826_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2340\/00015555-2774","article-title":"Chronic prurigo of nodular type: a review","volume":"98","author":"Zeidler","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.eclinm.2023.101826_bib2","article-title":"Diagnostic workup and evaluation of patients with prurigo nodularis","volume":"6","author":"Kwon","year":"2019","journal-title":"Medicines (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.eclinm.2023.101826_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/17512433.2021.1852080","article-title":"Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis","volume":"14","author":"Williams","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.101826_bib4","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","article-title":"Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus","volume":"84","author":"Elmariah","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.101826_bib5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2018.04.044","article-title":"Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: results of the European academy of dermatology and venereology network on assessment of severity and burden of pruritus (PruNet) cross-sectional trial","volume":"79","author":"Steinke","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.101826_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/jdv.15145","article-title":"The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries","volume":"33","author":"Brenaut","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.eclinm.2023.101826_bib7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jdin.2020.10.009","article-title":"Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis","volume":"2","author":"St\u00e4nder","year":"2021","journal-title":"JAAD Int"},{"issue":"2","key":"10.1016\/j.eclinm.2023.101826_bib8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","article-title":"Real-world prevalence of prurigo nodularis and burden of associated diseases","volume":"140","author":"Huang","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.eclinm.2023.101826_bib9","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1016\/j.jaip.2020.05.051","article-title":"Prevalence of prurigo nodularis in the United States","volume":"8","author":"Whang","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.eclinm.2023.101826_bib10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.21698","article-title":"Chronic prurigo","volume":"187","author":"Misery","year":"2022","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.101826_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3390\/vaccines9030303","article-title":"Pruritus as a distinctive feature of type 2 inflammation","volume":"9","author":"Garcovich","year":"2021","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.eclinm.2023.101826_bib12","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3778","article-title":"Impact of itch on sleep disturbance in patients with prurigo nodularis","volume":"101","author":"Gwillim","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"10.1016\/j.eclinm.2023.101826_bib13","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00403-020-02148-0","article-title":"The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis","volume":"313","author":"Janmohamed","year":"2021","journal-title":"Arch Dermatol Res"},{"issue":"2","key":"10.1016\/j.eclinm.2023.101826_bib14","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1111\/jdv.13827","article-title":"Anxiety, depression and suicide in patients with prurigo nodularis","volume":"31","author":"J\u00f8rgensen","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.101826_bib15","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","article-title":"IL-31: a new key player in dermatology and beyond","volume":"141","author":"Bagci","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"14","key":"10.1016\/j.eclinm.2023.101826_bib16","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3505","article-title":"Oncostatin M induction of monocyte chemoattractant protein 1 is inhibited by anti-oncostatin M receptor beta monoclonal antibody KPL-716","volume":"100","author":"Richards","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.101826_bib17","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/exd.14279","article-title":"Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta","volume":"30","author":"Hashimoto","year":"2021","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/j.eclinm.2023.101826_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"8","key":"10.1016\/j.eclinm.2023.101826_bib19","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.eclinm.2023.101826_bib20","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.jid.2019.03.278","article-title":"The oncostatin M receptor beta axis identified in prurigo nodularis","volume":"139","author":"Mikhak","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.eclinm.2023.101826_bib21","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.jid.2019.03.636","article-title":"KPL-716, anti-Oncostatin M receptor beta antibody, reduced pruritus in atopic dermatitis","volume":"139","author":"Mikhak","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.eclinm.2023.101826_bib22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/ijd.12645","article-title":"The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis","volume":"54","author":"Naegeli","year":"2015","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.eclinm.2023.101826_bib23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale: a new measure of pruritus","volume":"162","author":"Elman","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.eclinm.2023.101826_bib24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1477-7525-7-64","article-title":"Evaluation of the impact of fibromyalgia on patients' sleep and the content validity of two sleep scales","volume":"7","author":"Martin","year":"2009","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"10.1016\/j.eclinm.2023.101826_bib25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A\u00a0sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"issue":"12","key":"10.1016\/j.eclinm.2023.101826_bib26","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/jdv.15107","article-title":"Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need","volume":"32","author":"Pereira","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.eclinm.2023.101826_bib27","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/jdv.15040","article-title":"Prurigo Activity Score (PAS): validity and reliability of a new instrument to monitor chronic prurigo","volume":"32","author":"Polking","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.eclinm.2023.101826_bib28","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1111\/bcp.13669","article-title":"In\u00a0vivo affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody","volume":"84","author":"Reid","year":"2018","journal-title":"Br J Clin Pharmacol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023000032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537023000032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:16:50Z","timestamp":1762899410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023000032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":28,"alternative-id":["S2589537023000032"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.101826","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor \u03b2 antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2023.101826","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101826"}}